1. Home
  2. ICCC vs YI Comparison

ICCC vs YI Comparison

Compare ICCC & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$10.02

Market Cap

75.8M

Sector

Health Care

ML Signal

HOLD

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$5.01

Market Cap

57.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCC
YI
Founded
1982
2010
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Drug Stores and Proprietary Stores
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
75.8M
57.1M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
ICCC
YI
Price
$10.02
$5.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.0K
11.0K
Earning Date
05-15-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
N/A
EPS
0.21
N/A
Revenue
$26,493,169.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.64
N/A
52 Week Low
$4.52
$2.48
52 Week High
$10.25
$11.17

Technical Indicators

Market Signals
Indicator
ICCC
YI
Relative Strength Index (RSI) 73.69 41.58
Support Level $5.85 $5.33
Resistance Level N/A $7.18
Average True Range (ATR) 0.50 0.48
MACD 0.12 -0.02
Stochastic Oscillator 97.37 50.92

Price Performance

Historical Comparison
ICCC
YI

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

Share on Social Networks: